[A25-135] Nivolumab (colorectal cancer with dMMR or MSI-H, first line, combination with ipilimumab) – Addendum to Project A25-80
Last updated 18.12.2025
Project no.:
A25-135
Commission:
Commission awarded on 28.10.2025 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
First-line treatment of adult patients with unresectable or metastatic colorectal cancer with mismatch repair deficiency or high microsatellite instability
Unchanged after addendum: added benefit not proven
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
https://doi.org/10.60584/A25-135
| Project no. | Title | Status |
|---|---|---|
| A25-80 | Nivolumab (colorectal cancer with dMMR or MSI-H, first line, combination with ipilimumab) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2025-12-18 A G-BA decision was published.